Market Research Blog – Page 14395 – New Product Development

Pharmaceutical Lactose Market 2022 | Scope of Current and Future Industry 2031

Cloud based technologies are being implemented in drug manufacturing. Continuous developments in cloud based drug discovery platforms is expected to largely contribute to the growth of the global market for pharmaceutical lactose market. According to a new study by Future Market Insights (FMI), the pharmaceutical lactose market will reach US$ 605.9 Mn by 2021. Focus on research and development among drug manufacturers is consistently increasingly, in turn creating opportunities for the expansion of the market.

Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8756

Development of advanced manufacturing processes, technological innovations to produce quality medicines that are consistently safe and effective, have fueled pharmaceutical manufacturing. Recently, various drug shortages have been reported, leading to expansion of drug production facilities with advanced technologies. This will accelerate drug production and narrow down the supply-demand gap.

The ongoing expansion of production facilities with advanced technology accelerates the consumption of pharmaceutical lactose and is expected to lead to pharmaceutical lactose market growth across the globe

FMI’s report on the market for pharmaceutical lactose provides forecasts the demand for α-Lactose monohydrate to be considerably high. As a result of its increasing application in excipients, the market will continue registering impressive growth. FMI has forecast the product category to account for over half of sales recorded in the market through the forecast period.

Key Takeaways from Pharmaceutical Lactose Market Report

Pharmaceutical lactose sales will show improvement by 0.2% between 2020 and 2021
Backed by presence of a sophisticated healthcare infrastructure, the U.S. will account for over 60% of sales in North America
The U.K. will remain a strong market for sales within Europe, exhibiting 4.4% Y-o-Y growth in 2021
Germany and France will offer attractive growth opportunities driven by increasing focus on improving healthcare
Government support to aid expansion in Japan, South Korea, and China

“Innovation has become a key factor in recent times as there is a continuous need for developing something new. This demand has resulted in pharmaceutical lactose manufacturers focusing increasingly on expansion of their R&D facilities in a way that can support innovations in line with the demand from the end-use manufacturers. For this reason, all types of companies of pharmaceutical lactose, be it small, medium, or large, are increasingly investing in research and development. A significant amount of the sales revenue is being used for the funding of research and development, “says FMI analyst.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-8756

Innovations in Drug Discovery Services to Present Growth Opportunities

The use of artificial intelligence in drug discovery sector is enhancing the productivity of the process. It is being increasingly adopted to discover novel biological targets to develop new medications by carrying out comparison of exhaustive data collected from the tissue samples of healthy ad diseased individuals. Increasing number of huge pharmaceutical giants such as are exploring the use of artificial intelligence via alliances with start-up companies, the main aim being to predict and analyze molecular behavior for the development of a useful medicine. The penetration of AI in pharmaceutical leads to new drug discovery and amps up the demand of pharmaceutical lactose.

Who is Winning?

Some of the key players operating in the pharmaceutical lactose market are Avantor, Inc., Ba’emek Advanced Technologies Ltd (Tnuva Group), Koninklijke FrieslandCampina N.V., Armor Pharma, Hilmar Ingredients Inc., Hoogwegt Groep B.V., Kerry Group plc, Lactose (India) Limited, Merck KGaA, BASF SE, Milei GmbH, Alpavit Käserei Champignon Hofmeister GmbH & Co. KG, and other playes.

Key players of pharmaceutical lactose are focusing on new product launches, partnership, acquisition, mergers, and joint venture to expand its product portfolio as well as to strengthen its distribution channel.

In 2019, Kerry Group launched Aero Flo brand inhalation grades of lactose. Aero Flo® brand inhalation grades of lactose have been specifically developed for use in dry powder inhalers for pulmonary delivery of pharmaceuticals.
In 2019, LBB Specialties signed a strategic partnership deal with Meggle for the distribution of Meggle’s Pharmaceutical Lactose excipients, including lactose for inhalation formulations, in the United States.

Get Valuable Insights into Pharmaceutical Lactose Market

Future Market Insights, in its pharmaceutical lactose report, presents an unbiased analysis of the global pharmaceutical lactose market, covering demand data and forecast figures for the period between 2021 and 2031. The study divulges compelling insights into growth witnessed in the pharmaceutical lactose market. Based on product type the pharmaceutical lactose market can be segmented into Β-Lactose, α-Lactose monohydrate, Amorphous lactose, and Spray dried lactose. Regionally, the pharmaceutical lactose market covers North America, Latin America, Europe, East Asia, South Asia and Oceania and Middle East & Africa (MEA).

Buy Complete Report @ https://www.futuremarketinsights.com/checkout/8756

Contact Us:

Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Narcolepsy Treatment Market Is Growing with new Opportunities at a CAGR of 5.7% during the forecast period 2022-2028

Revenue from narcolepsy treatment, globally is projected to stand at a valuation of US$ 6.67 Bn, registering an annual growth rate of 5.7 percent, from 2022-2028. Future Market Insights (FMI), in its newly published market intelligence outlook, highlights substantial demand for narcolepsy treatment in North America. Narcolepsy treatment landscape in Europe, will witness significant revenue growth given the rising affinity toward adoption of prescription treatments and adherence to the same on a long term basis.

Asia Pacific among other emerging economies including MEA and Latin America, on the other hand, are expected to showcase positive trends towards the adoption of narcolepsy treatment, due to:

Ask for the Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-7641

Strong distribution pipeline of the narcolepsy drugs.
Emerging global and local biopharmaceutical companies.
Increasing incidences of Obstructive Sleep Apnea (OSA) in Latin America. Obesity is reported to be the most common risk factor.
Prevalence of moderately severe sleep apnea is estimated to be around 5% in women and 10% in men in South Africa. It is estimated that up to 90% of patients are undiagnosed.
Prevalence of sleep apnea is more severe in the developing countries due to the lack of skilled physicians

In term of key forward market strategies, the primary objective manufacturers in the narcolepsy treatment market is to expand their footprint in the various regional markets, in order to solidify their market position.

Key Findings from the Regional and Competitive Landscape Analysis of Narcolepsy Treatment Market

Leading narcolepsy treatment manufacturers are prioritizing regional-specific product development. The product portfolio expansion is mostly targeted in Asia Pacific.
Apart from new product development—mostly arising from the presence of low cost generic versions of patented drugs, strategic partnerships and acquisitions with pave way for further business expansions.
Manufacturers in the global narcolepsy treatment are also focused towards introducing new research and development units in different geographic regions.
Industry leaders are focusing on maintaining long-term partnerships with pharmacies- in hospital and retail, drug stores, and e-commerce. Sales through e-commerce distribution channel is expected to contribute a significant revenue share in the global narcolepsy treatment market.
FMI, has also noted an increasing focus on reformulation of well-known products and combinations, by manufacturers in North America in order to achieve higher sales and wide penetration.

There is a conscious shift from OTC medication to devices treating narcolepsy, driving significant revenue growth for the devices segment compared to drugs. Growing incidences of inappropriate medication and addiction, translating into severe side effects including headache, prolonged drowsiness, daytime memory and performance problems, allergic reactions, and death in some cases, is the key driving factor. These side effects are associated with OTC as well as prescription-based sleep aids.

Growing demand to treat narcolepsy with BiPAP is expected to push this segment of devices—predicted to expand at the highest CAGR. Moreover, devices in portable and available-for-rent formats, will translate into higher adoption rates, throughout the forecast period. Portable Continuous positive airway pressure (CPAP) devices are lighter and smaller and can also be used as a home based unit, further reducing the dependency on OTC pills and prescription drugs.

While explaining the growth trajectory of narcolepsy treatment market, a senior analyst from the healthcare domain underscores growing healthcare expenditure and rising incidence cases of fracture fixation and orthopedic disorders as key factors contributing to the demand of narcolepsy treatment though 2028. “Regulatory impositions by various global authorities including the FDA and European Commission along with currency fluctuations, regulations and changing taxation policies are some high-impact factors pushing the global demand for narcolepsy treatment”, the analyst further explains.

Critical Market Restrainers

Although the narcolepsy market is expanding at a robust CAGR, long waiting time for sleep services, lack of awareness and delayed diagnosis, severe side effects of sleep aids medication, lack of proper documentation for the usage and licensing of sleeping pills, and improper equipment regulations are some critical factors projected to restrain the growth of narcolepsy treatment market.

Get in-depth TOC of this Report with figures: https://www.futuremarketinsights.com/reports/narcolepsy-treatment-market/table-of-content

About the Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Beet Pulp Market 2022 Outlook, Current and Future Industry Landscape Analysis 2031

Rising cases of chronic ailments have been encouraging consumers to adopt healthy eating. There is higher focus towards preventive healthcare, which is expected to fuel the demand for plant-based ingredients such as beet pulp. According to a study by Future Market Insights (FMI), the beet pulp sales are poised to surge considerably in the coming years. The market is expected to surpass US$ 2.5 Bn valuation in 2021.

The demand for dried pulp is expected to be the highest. It is likely to account for over 70% of beet pulps sold. East in transportation and lesser threat of damage or contamination will continue fuelling demand in this category.

Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-10821

Beet pulp is not only rich in nutrients, minerals, and vitamins but is also rich in unique phyto-constituents, which have numerous medicinal properties. It is anti-oxidant, anti-microbial, anti-depressant, anti-fungal, diuretic, anti- inflammatory, expectorant, and carminative, making it “superfood” for today’s generation.

Beet pulp also is a rich source of nitrates and sugar content making it an energy dispenser for consumers. The increasing health and wellness consciousness among the customers is drastically leading to an increasing penetration of beet pulp in end user applications.

Key Takeaways from Beet Pulp Market Report

The demand for beet pulp is expected to rise consistently, enabling the market register 5.9% CAGR between 2021 and 2031
Popularity of plant-based ingredients will drive sales in U.S., enabling it to account for over 88% of beet pulp sold in North America in 2021
The U.K. market will register a steady 2.5% y-o-y growth in 2021
Increasing veganism trend will support growth in France and Germany
Government initiatives undertaken to boost public health will support growth in China, followed by Japan and South Korea

“Livestock owners nowadays have become well aware about the livestock feeds they buy and the nutritional benefits it offers. Nutrition is an important factor in recent times and sales of products failing to qualify consumer expectation often get negatively affected. Thus, the manufacturers of livestock feed have started incorporating high nutritional value in their products. For this purpose, they have started deriving nutrition from sources such as plants to increase the nutritional content of livestock feed, this will boost the beet pulp market” said a lead analyst at FMI

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-10821

Rise in Livestock Ownership Drives the Beet Pulp Market

The primary driver of the beet pulp market is the increasing number of livestock ownership. The increasing adoption of cows and horses as companion for families is driving the beet pulp market.

Suppertime is the happiest time for livestock, and every livestock owner strives to feed their animals a healthy, flavourful meal. Social comfort, protection, and companionship that animals provide are key factors encouraging them to raise animals. As a result the growing number of livestock owners, in turn fuelling the demand for livestock feed.

Furthermore, a number of businesses are focusing on developing new flavours for their products. The majority of animal feeds contain wheat, corn, and soy, which are combined with animal fats to give it a meaty flavour. Furthermore, safety regulations placed on livestock feed could contribute to an increase in demand for beet pulp market during the forecast period.

Who is winning?

Some of the key players operating in beet pulp market Amalgamated Sugar, Michigan Sugar, Midwest Agri, Tereos, British Sugar, Nordzucker, Ontario Dehy Inc., American Crystal Sugar, Delta Sugar Company and many others. Key players of beet pulp are building strategies that will make their production line more efficient in order to get more output.

For instance, Delta sugar company, which is leading manufacturer of in beet pulp market, has focused on effective and efficient production process that produces ±140.000 tons of beet pulp. This Company exports to markets in Europe and in the domestic market.

Get Valuable Insights into Beet Pulp Market

Future Market Insights, in its new report, presents an unbiased analysis of the global beet pulp market, covering historical demand data and forecast figures for the period between 2021 and 2031. The study divulges compelling insights into growth witnessed in the market. Based on the beet pulp market on basis of Product Type, has been classified as wet pulp, pressed pulp, dried pulp, ensiled pulp. Based on Sales Channel beet pulp market are classified as Direct Sales, Modern Trade, Specialty Store, Departmental Store, Convenience Store, Online Retailers, Other Retail Formats. Based on category type beet pulp market is classified as Molassed, Unmolassed. Based on livestock type beet pulp market is classified as Cow, Horse, Sheep, Goat, Pig, Buffaloes, Mules, Asses. Regionally, beet pulp covers North America, Latin America, Europe, South Asia, East Asia, Oceania, MEA.

Buy Complete Report @ https://www.futuremarketinsights.com/checkout/10821

Contact Us:

Lateral Flow Assays Market Overview & In-depth Analysis by Application: Clinical Testing, Veterinary Diagnostics, Food Safety & Environmental Testing- Forecast to 2022-2032

According to a recent lateral flow assays market report by Future Market Insights (FMI), the lateral flow assays market was valued at US$ 11 Bn in 2021, is projected to reach US$ 12.5 Bn by 2026, and is anticipated to grow at a CAGR of around 2% over the projected period of 2022-2032.

The high rate of infectious diseases around the world, explosive growth in the geriatric population, escalating demand for point-of-care testing, and increased use of home-based

rapid lateral flow devices are all boosting lateral flow assays market forward. The significant restraints are doctors’ and patients’ reluctance to change existing diagnostic techniques and the low accuracy of lateral flow assays.

Request for the Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-14271

The affordable cost of lateral flow assays devices and the fact that no trained personnel is required to run the tests are two factors driving up demand for lateral flow assays-based devices for COVID-19 testing.

The growing adoption of kits & reagents due to innovations and benefits of lateral flow assays rapid tests over laboratory tests the high number of lateral flow assay rapid detection kits launched by healthcare companies, predominantly for lateral flow assay COVID-19 testing, are all factors contributing to the large share of the kits & reagents segment.-

Sandwich assays have a considerable part of the lateral flow assays market due to the growing use of sandwich assays in medical testing and the benefits of sandwich assays.

Despite the fact that lateral flow assay tests are simple to implement and less affordable than laboratory testing, they are less reliable.

Due to the apparently limited accuracy of the lateral flow assay kit, most doctors and patients prefer molecular studies to fast tests for more accurate COVID-19 diagnosis. As a result, major diagnostic lateral flow assays market participants are concentrating their efforts on developing more laboratory-based infectious disease testing solutions.

Infectious disease lateral flow assays diagnostics, cardiac disease diagnosis, and veterinary applications are typical applications for lateral flow tests. However, the use of lateral flow technology has grown in various new applications in recent years.

Potential applications for lateral flow tests include saliva diagnostics, behavioural health, agriculture (crop quality testing), biowarfare (anthrax detection), environmental testing, and food microbiology.

Lateral flow assay (immunochromatography tests/lateral flow immunoassays) technologies continue to dominate the point of care diagnostic market through 2024.

The acquisition and validation of vital reagents are one of the most challenging elements of producing lateral flow assay tests. Antibodies used in assays must be evaluated for accuracy, specificity, stability, and reproducibility, as any reagent flaws can cause the lateral flow assay to fail. Another obstacle is lateral flow assays diagnostics after an antibody or antibody pair has been found.

Key Takeaways

The Kits & Reagents segment is anticipated to grow at a rapid CAGR of 5.3% during the forecast period.
The clinical testing segment accounted for 90.9% of the lateral flow tests market.
With a lateral flow tests market share of 70.9% in 2020, sandwich assays dominated the lateral flow tests market.
Blood samples were the most preferred, with a 53.1% lateral flow tests market share.
The hospitals and clinics segment was the most favoured, with a lateral flow tests market share of 37.6%.
China, the world’s second-largest economy, is expected to reach a lateral flow tests market size of US$917 million in 2027, with an annual growth rate of 8.8%.
Within Europe, Germany is expected to show a lateral flow tests market growth at a 4.8% compound annual growth rate (CAGR), while the rest of the European market will reach US$917 million by 2027.
The Asia Pacific region is expected to increase at a CAGR of 4.2% during the forecast period.

Competitive Landscape

Some companies have increased their lateral flow tests market share through various strategies such as mergers and acquisitions. In contrast, others invent new diagnostic market test methods and provide innovative goods to maintain their market share.

Abbott Laboratories (U.S.), F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (U.S.), Siemens AG (Germany), Becton, Dickinson and Company (U.S.), bioMérieux S.A. (France), Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (The Netherlands), PerkinElmer, Inc. (U.S.), and others are some of the major players in the lateral flow assays market.

Becton, Dickinson and Company sought permission for an OTC fast antigen test utilising the Scanwell Health Mobile App in August 2021.
Becton, Dickinson and Company collaborated with USA Track & Field (USATF) (U.S.) in April 2021 to provide athletes using the B.D. veritor plus system with swift COVID-19 testing.
Qiagen N.V. (Netherlands) procured NeuMoDx Molecular, Inc. (U.S.) in September 2020 to expand Qiagen’s diagnostics instrument product portfolio and bolster its automated molecular testing market position.
Merck KGaA (Germany) announced in July 2020 the expansion of a new production plant in Buchs at USD 21 million (Switzerland).

Request for the complete TOC of this Report with figures: https://www.futuremarketinsights.com/reports/lateral-flow-assays-market/table-of-content

About the Healthcare Division at Future Market Insights

Laboratory Information Systems (LIS) Market stood at around US$ 1.9 Billion in 2022, and is slated to increase at a CAGR of 10.2% to reach a valuation of US$ 4.2 Billion by 2022-2030

Global laboratory information system (LIS) market revenues are set to grow at 10.2% CAGR through 2030, according to an updated edition by Future Market Insights (FMI). The 2022-2030 version of the report builds upon the widely cited previous version, and incorporates the latest developments, notably, the impact of COVID-19 pandemic on this market.

Over the years, the healthcare industry has witnessed massive technological advancements in the form of automation, big data analytics and cloud computing. The most important aspect in the industry is the need to reconcile administrative operations with caregiving operations. This has become possible through the introduction of advanced laboratory testing systems.

Click to get Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-875

Laboratories are the foundational stone for primary healthcare administration. It is the laboratories which are the site for drug development and API formulations. To accelerate the effectiveness of these functions, there is a need to streamline mundane operations such as data collation, assimilation and record maintenance.

The need for systematic data documentation to reduce paperwork is primarily driving the laboratory information systems market. Significant adoption has been witnessed since the COVID-19 pandemic’s onset, enabling healthcare providers to concentrate on drug and vaccine development by smoothening data collection procedures.

Key Findings

Europe & North America will remain lucrative, accounting for 4/5^th of the revenue pie
Cloud-based laboratory information systems to register maximum increase during the forecast period
Vendors are increasingly capitalizing on developing LIS software for various healthcare verticals
Hospital-grade laboratory information systems are gaining significant momentum

COVID-19 Impact Analysis

Clinical laboratories are finding it unnerving to cope with the rapid influx of COVID-19 testing samples, impacting their ability to provide accurate testing. Incorporation of automated solutions is therefore anticipated to relieve these clinics of this uncertainty by promoting efficient testing of voluminous samples.

Prominent players in the laboratory information systems landscape are collaborating with public and private sector organizations to employ advanced technologies for implementing COVID-19 testing capabilities. For instance, LabWare Technologies has collaborated with the National Health Service to provide laboratory management software to healthcare settings across the United Kingdom.

Thus, the market shall witness a significant upsurge during the short-term forecast period, with an increasing number of healthcare providers accelerating the uptake of technologically advanced laboratory information systems.

“Manufacturers are increasing their presence across emerging markets and forging effective distribution networks with regional players. This is helping them expand their outreach and broaden their customer base,” opines the FMI analyst.

Competitive Intelligence

The global laboratory information systems market is highly fragmented, characterized by the presence of over 50 vendors. Prominent players include: Cerner Corp., Evident, McKesson, Medical Information Technology (MEDITECH), Epic Systems Corporation, SCC Soft Computer, Roper Technologies Inc., CompuGroup Medical and LabWare.

With regard to product launches, Cerner Corporation launched CommunityWorks Foundations, a tailor-made cloud-based technology platform for rural and critical access hospitals in July 2020. This technology shall prove instrumental in reducing overhead costs and reducing lengthy implementation procedures. The platform enables hospitals to maintain electronic health records, reducing immense amount of paperwork.

Recently, in August 2020, Medical Information Technology (MEDITECH) partnered with TECHNATION Health in Canada. This collaboration is aimed at enhancing the privacy and security framework of healthcare providers across the nation, ensuring better patient data security. The solution involves provision of cybersecurity and data sovereignty among other objectives.

More Insights on the Laboratory Information Systems Market

A recent market study published by FMI on the laboratory information systems market includes the global industry analysis of 2015-2021 & opportunity assessment for 2022-2030, and delivers a comprehensive assessment of the most important market dynamics. The market is segmented on the basis of component (software, hardware, and services), delivery mode (on-premise and cloud based), and end user (hospitals, clinics, independent laboratories, and others), across seven prominent regions.

Click to get TOC of this Report with figures: https://www.futuremarketinsights.com/reports/laboratory-information-systems-market/table-of-content

About the Healthcare Division at Future Market Insights

Vaccines Market Overview & Analysis by Technology: Conjugate Vaccines, Inactivated & Subunit Vaccines, Live Attenuated Vaccines- Forecast to 2022-2032

The global vaccines market size is expected to reach US$ 120 Bn by 2032, growing at a 10% CAGR over the forecast period. The advent of existing and re-emerging infectious diseases, expanding industry reforms to promote vaccine R&D, growing public funding for developing drugs, and increasing immunization emphasis are all driving the growth of vaccines.

Experts warn that future pandemics and outbreaks might be even more deadly than COVID-19. Diseases could arise primarily based on pathogens into human, animal, or plant populations for terrorist goals. The expanding presence of infectious diseases will ensure a continuous and growing demand for vaccines in the coming years.

Furthermore, the advent of new diseases will result in increased R&D spending, a robust pipeline, and new vaccination prospects for significant populations.

Download the Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-14284

Attributes	Details
Vaccines Market CAGR (2022 – 2032)	10%
Vaccines Market (2032)	US$ 120 Bn
Vaccines Market Attraction	Advanced technology and cost efficiency are increasing the vaccines market growth.

Due to their large patient populations and rising disposable incomes, emerging regions such as India, China, and Southeast Asia provides an attractive potential for the vaccination business. Major market companies have been enticed to engage in these economies because of their growth potential.

As per emerging vaccines market trends, various organizations and institutions, such as GAVI, are also working to improve vaccine use in impoverished countries, for example, by distributing vaccines at reasonable prices. As a result, these countries have become vital growth hotspots in the vaccine market.

Another vaccines marketing strategy is the rise in low-cost vaccinations. To expand the reach of immunization programmes in these economies, companies are investing in and focusing on creating inexpensive, low-cost vaccines.

Vaccines have a greater storage and distribution cost than any other pharmaceutical product because they require specific equipment and monitoring systems. Vaccine quality might be harmed by a lack of suitable storage and delivery facilities. As a result, vaccines market share is being stifled by the heavy price of vaccine production and storage.

Key Takeaways:

The high prevalence of infectious illnesses, government organizations’ continued growth in vaccine development, market participants’ expanding R&D investments, and mandated reporting are some of the essential drivers propelling the sales for vaccines globally.
The substantial proportion of this category in the vaccines market is ascribed to the release of new multivalent vaccines, increased funding by critical players in multivalent vaccine R&D, and technological innovations in multivalent vaccine development.
The vaccines market report states that the influenza category is expected to grow fastest. The global consumption of influenza vaccines is supported by rising knowledge of the necessity of influenza vaccination, increased government initiatives to prevent influenza, and more clinical studies.
The vaccines market trends state that intramuscular vaccine delivery is expected to grow the fastest. The convenience of intramuscular injection propels the segment, and the fast absorption of vaccines is provided in this way.

“The high frequency of diseases, increased government immunization campaigns, technological advancements in the vaccine business, a solid vaccine pipeline, and the advent of the COVID-19 pandemic are all factors to consider,” opines an FMI analyst.

Competitive Landscape:

Sanofi (France), Daiichi Sankyo Co., Ltd. (Japan), Merck & Co., Inc. (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), CSL Limited (Australia), Emergent BioSolutions Inc. (US), Pfizer Inc. (US), and AstraZeneca PLC have the highest market share by the company as highlighted in the global vaccines market report.

In August 2021, GlaxoSmithKline plc filed a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for their investigational vaccine PRIORIX, which seeks authorization to be used against measles, mumps, and rubella (MMR) in the United States. The vaccine was first licensed in Germany and is now approved in more than 100 countries around the world.
INOVIO Pharmaceuticals announced in June 2021 that it is expanding its collaboration with Advaccine Biopharmaceuticals Suzhou Co Ltd. to conduct a Phase 3 trial for their investigational COVID-19 DNA vaccine INO-4800, in patients aged 18 and up in several countries, particularly in Latin America and Asia.

Download the Complete TOC of this Report: https://www.futuremarketinsights.com/reports/vaccines-market/table-of-content

About the Healthcare Division at Future Market Insights

Prostate Health Market is Anticipated to Reach & Grow with a CAGR of 9% During the Time Period of 2022-2032

The prostate health market is predicted to advance vigorously. It is poised to attain a CAGR of 9% during the forecast period 2022-2032, according to the prostate health market report by Future Market Insights (FMI).

Grants for BPH treatment research and the fact that obesity causes several mechanisms, including increased sympathetic nervous activity, increased inflammation process, and oxidative stress, all of which are conducive to the development of BPH, are likely to accelerate prostate health market growth.

Cancer patients are at higher risk of COVID-19 infection than adults with good prostate health, according to major regulatory bodies around the world (such as the WHO, MHRA, TGA, and EMA) and screening, diagnostic exams, and surgical procedures in hospitals and cancer centres are severely limited or postponed.

To remain ‘ahead’ of your competitors, request for a sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-14282

As a result, caregivers and hospitals can expect delays in elective surgeries and screening procedures.

However, since the second half of 2020, the market has gradually increased due to an increase in the number of oncology appointments and rise in adoption of prostate health therapies, among other things, as a result of efforts to clear backlogs and new cases, which further shapes the prostate health market future trends.

Other factors that contribute to the demand for prostate health treatment include an increase in demand for prostate cancer treatment and management and an increase in the use of hormonal agents in non-metastatic castration-resistant (nmCRPC) and metastatic hormone nave (mHNPC) prostate cancer settings.

Moreover, the developing economies’ untapped potential presents lucrative prostate health market opportunities during the forecast period. Prolonged treatment times and low demand for prostate cancer medical treatment drugs in developing countries, on the other hand, are expected to shrink the prostate health market size.

Though both drugs and surgery can treat BPH and improve prostate health, they have significant side effects. Dizziness, orthostatic hypotension, and rhinitis are common alpha-blocker side effects. These are of particular concern in the elderly, as they can result in significant morbidities such as falls, and subsequent injuries are expected to impact the prostate cancer treatment adoption trends.

As per the prostate health market study, the market is forecasted to garner a worth of about US$ 50 Bn by 2026.

Key Takeaways:

Due to significant growth in the geriatric population and a large target patient population, prostate cancer is expected to account for the largest share of the prostate health market based on disease indication.
Neurostimulation devices are anticipated to have the highest prostate health market share in the type market.
Attributing to the strong presence of hospital pharmacies around the world and the convenience offered by hospital pharmacies, the hospital pharmacies segment is projected to lead the prostate cancer treatment market.
The crucial factor for Asia-Pacific’s market growth can be credited to the rapidly growing patient population for benign prostatic hyperplasia in the region, particularly in Japan, China, South Korea, Hong Kong, and Taiwan.

“USFDA took steps to boost the growth of the cancer therapy market by approving drugs that are still in the clinical stage, thereby speeding up clinical trials and investments in R&D by businesses and research organizations can be credited to market growth in the United States which is a major contributor to the North American prostate health market. Moreover, favourable reimbursement policies, a strong healthcare infrastructure, and some other emerging trends in the prostate health market such as product launches have also contributed to the market’s rapid growth.” asserts an FMI analyst.

Competitive Landscape:

AstraZeneca plc, Bristol-Myers Squibb Company, Astellas Pharma Inc., F. Hoffmann-La Roche AG, Bayer AG, erring Pharmaceuticals Inc., Ferring Pharmaceuticals Inc., Ipsen Pharma, Johnson & Johnson, Takeda Pharmaceutical Company Ltd. and GlaxoSmithKline Plc are among the key players in the prostate health market.

Within the global prostate cancer diagnostic market, there are several significant drug and equipment manufacturers, and their status as a significant players is primarily based on specific product markets.

Players have been looking for novel ways to expand their market through innovative prostate product launches.

Recent developments in the prostate health market are as follows:

The first commercial production of Axumin (fluciclovine) in Italy was announced by Blue Earth Diagnostics, with the first Italian patients being dosed.
Myovant partnered with Pfizer to commercialize Orgovyx (relugolix), a prostate cancer drug.
In the United States, Dr Reddy introduced generic Abiraterone Acetate Tablets USP, 250 mg, which is a therapeutic equivalent generic version of Zytiga (abiraterone acetate) for prostate cancer.

Request for the Complete TOC of this Report: https://www.futuremarketinsights.com/reports/prostate-health-market/table-of-content

About the Healthcare Division at Future Market Insights

Plant Derived Proteins Market Witnessing Growth with the Key Player: Amgen Inc, Abbott Laboratories, AstraZeneca, Merck KGaA & Baxter International, 2022-2029

Production and commercialization of biopharmaceutical proteins with higher therapeutic efficacy have formed a progressive landscape that continues to push the growth of plant derived proteins market. A new Future Market Insights (FMI) report forecasts that the plant derived proteins market will experience a major upturn towards 2029, reaching a value of around US$ 185 Mn. Production of three main therapeutic protein classes, including antibodies, vaccines, and replacement proteins such as albumin, insulin, growth factors, and cytokines will remain industry’s prime focus area.

Plant derived proteins are recognized as natural and environmentally-sustainable than microbial and mammalian cells. Owing to these benefits, there has been an increasing demand for such proteins from biopharmaceutical companies, as raw materials for therapeutic drug production, creating an absolute opportunity for growth of the plant derived proteins market.

Get the Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-11038

Key Takeaways of Plant Derived Proteins Market Study

The production of therapeutic proteins for disease treatment will gain traction, contributing more than 70% to global market revenues in 2029.
Owing to low setup cost, transient plant expression systems (carrot or tobacco) remains preferred among protein manufacturers.
Regenerative medicine-therapeutic agents continue to be the leading application area, on the back of their relatively cheap price point.
Biopharmaceutical companies represent the leading consumer industry of plant derived proteins, with over 50% share in market throughout the forecast period.
North America continues to lead, whereas East Asia holds the promise of lucrative opportunities, owing to several healthcare programs.

“Rising demand for passive immunization have led to development of new plant based platforms, which could transform and express recombinant therapeutic vaccines and antibodies more effectively with increased stability, high yield, and high quality,” says the FMI study.

Acquisition Key Strategy Followed by Leading Market Players

Leading manufacturers in the plant derived proteins market are focusing on regional acquisition strategy to enhance their product portfolio and expand their regional presence. For instance, in 2020, Denka buys pharming pioneer Icon Genetics, which is a leading manufacturers of therapeutic proteins in plants. In 2014, Kentucky BioProcessing, Inc. was acquired by Reynolds American Inc., which is a wholly owned subsidiary of tobacco manufacturing company British American Tobacco plc.

Interested in more insights on the build-up of plant derived proteins market?

Plant derived proteins market, a new study from future market insights, opines on the production of plant derived proteins from 2014 – 2021 and presents demand projections from 2022 – 2029 on the basis of; plant type (tobacco, carrot, rice, barley and others), protein type (industrial proteins & enzymes, therapeutic proteins cell culture functional proteins and others), application (regenerative medicine-therapeutic agents, regenerative medicine-functional material, cell culture application and others), platform (in-vitro culture system, whole plants and others) and end user (biopharmaceutical companies, academic & research institutes, contract research organization (CROS), contract manufacturing organization (CMOS)) across seven prominent regions.

Get the TOC of this Report with figures: https://www.futuremarketinsights.com/reports/plant-derived-proteins-market/table-of-content

About the Healthcare Division at Future Market Insights

Aspiration & Biopsy Needles Market In-Depth Analysis, Growth Strategies and Comprehensive Forecast to 2022-2032

The aspiration and biopsy needles market is forecasted to be worth US$ 0.87 billion in 2021, with a CAGR of 7% forecast to hit US$ 1.83 billion by 2032.

Many growth-promoting factors are driving the aspiration and biopsy needles market, along with rising demand for minimally invasive surgeries, greater cancer awareness campaigns by global health organizations and governments, and rising cancer diagnoses.

Cancer screening, cancer management visits, and cancer biopsy procedures have all decreased significantly due to the COVID-19 pandemic. In addition, cancer screening operations were hampered due to the lockdowns, resulting in a reduction in demand for biopsy needles.

Since March 2020, COVID-19 has resulted in a substantial drop in imaging operations (for all modalities).

Download the Report Sample here: https://www.futuremarketinsights.com/reports/sample/rep-gb-14287

Attributes	Details
Aspiration & Biopsy Needles Market CAGR (2022 – 2032)	7%
Aspiration & Biopsy Needles Market (2026)	US$ 1.29 Bn
Aspiration & Biopsy Needles Market Attraction	Asia Pacific to gain momentum

The aspiration and biopsy needles market players have an opportunity to expand their presence in the unexplored aspiration and biopsy needles market of emerging nations. For example, in the Middle East and Asia-Pacific, the senior population and cancer prevalence rapidly rise, yet biopsies are mostly administered using the standard surgical approach.

Emerging economies such as India, China, and South Korea provide market participants with high-growth potential. As a result, the Asia Pacific market is predicted to grow at the fastest CAGR during the forecast period.

The driving factors of the aspiration and biopsy needles market are fueling the global of this regional aspiration and biopsy needles market are increased government initiatives for cancer diagnostics and screening, increased research activities, and the high incidence of cancer in significant Asia Pacific countries such as India and China.

As a result, enterprises in the area have begun merging several imaging modalities to improve the operation and lower the cost for patients. Furthermore, as individuals in this country become more informed about efficient cancer diagnostic procedures, aspiration and biopsy needles market manufacturers have the potential to expand by focusing on developing-country clients.

“India is facing an acute shortage of oncologists, radiotherapists, and surgical oncologists. With 1.8 million cancer patients in the country, there is only one oncologist to treat every 2,000 patients.”

Radiologists and surgeons use biopsy needles to examine abnormalities at a specific site. Since these treatments include cuts and incisions for obtaining tissue samples, patients may become infected. In addition, aspiration and biopsy needles are frequently reused, which raises the risk of infection during these operations. Although the reuse of biopsy needles is discouraged by healthcare authorities and product manufacturers, the practice persists, particularly in underdeveloped nations.

Buy Report from this link: https://www.futuremarketinsights.com/checkout/14287

Key Takeaways:

By 2026, the global aspiration and the biopsy needle are estimated to reach US$ 1.29 billion.
Core needle biopsy (CNB) is the most common type of biopsy, accounting for over 47% of the total aspiration and biopsy needle market in 2019.
Hospitals accounted for 74.3% of the entire aspiration and biopsy needle market in 2019.
North America is the world’s largest consumer area, accounting for 35.2% of worldwide aspiration and biopsy needle market sales in 2019.
Europe is a significant consumer aspiration and biopsy needle market, accounting for 30.46% of worldwide sales.
Vacuum-assisted biopsy, biopsy guns, and biopsy forceps and punches will all develop at far faster rates than Fine Needle Aspiration, with CAGRs of 3.97 percent, 3.70 percent, and 1.63 percent, respectively.

Competitive Landscape

To expand their portfolio and streamline the competition, manufacturers in the aspiration and biopsy needles market have acquired other companies in recent years.

Olympus Corporation, Boston Scientific Corporation, Medtronic plc, Stryker Corporation, Becton, Dickinson and Company, Argon Medical Devices Inc., CONMED Corporation, Merit Medical Systems Inc., Sterylab s.r.l., Cook Medical LLC, and Cardinal Health Inc. are among the significant global aspiration and biopsy needles market manufacturers.

The following are some noteworthy developments in this aspiration and biopsy needles market’s competitive landscape:

In September of last year, Olympus Corporation of Tokyo gained FDA certification for its EZ Shot Plus 25 G needle.
Olympus Corporation, based in Tokyo, introduced aspiration biopsy needles with Side Port – Reusable to the market in April 2016. (NA-2C-1)
In the United States, Cook Group Incorporated released the EchoTipProCore 20 Gage Needle a few years ago. It was designed for fine needle biopsy with ultrasound guidance (FNB).
In January 2021, Hologic, Inc. acquired SOMATEX Medical Technologies GmbH, a leader in biopsy site biomarkers, for USD 64.00 million. The acquisition funds Hologic, Inc.’s strategy to deliver a varied range of novel solutions for breast cancer treatment. Hologic, Inc. would be able to expand the breast cancer marker portfolio.

Download the TOC of this Report with figures: https://www.futuremarketinsights.com/reports/aspiration-and-biopsy-needles-market/table-of-content

About the Healthcare Division at Future Market Insights

Radiation-Induced Myelosuppression Treatment Market valuation is projected to top US$ 3.5 Billion in 2028.

[207 Pages Report] Rapidly improving healthcare infrastructure and reimbursement scenario has been a major booster for the healthcare industry in developing regional markets. With incessantly increasing number of cancer cases, it is more likely that the subsequent demand for a wide range of treatments adopted to treat cancer patients would also remain on a constant rise over the course of coming years.

Radiation therapy has been a significant part of cancer treatment and the consistently high success rate associated with radiotherapy is projected to further push demand for radiation-induced myelosuppression treatment worldwide.

A new market research study on global radiation-induced myelosuppression treatment forecasts steady growth for the market in the next few years. Future Market Insights projects a moderate, just-under 4% yearly growth outlook, in 2022 and ahead.

Nutropenia is foreseen to generate maximum demand for radiation-induced myelosuppression treatment, whereas injectables are identified to hold a substantial share in the total market value, based on the route of administration of radiation-induced myelosuppression treatment. Thrombocytopenia and anemia are likely to present lucrative opporunities for radiation-induced myelosuppression treatment providers.

Report tracks key factors driving revenue growth of the market –

Increasing prevalence of cancers
Early diagnosis, promising improved chances of positive outcomes
Fostering R&D funds supporting cancer research
Strong product pipeline
Bolstering adoption of chemo-radiotherapy in cancer treatment

radiation induced myelosuppression treatment market

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-8116

In the backdrop of patent expiry, a majority of market leaders are shifting their focus to the expansion of product pipeline of a wide range of innovative formulations, likely to shape the radiation-induced myelosuppression treatment landscape.

Myelo001 by Myelo Therapeutics GmbH recently received an FDA approval as an orphan drug to be used in the ARS (acute radiation syndrome) treatment.
Mylan NV and Pfizer Inc. also reveived FDA approvals for their recently launched biosimilars – Epogen and Neupogen, and Neulasta respectively.

Patent expiry of originator biologics formulations is creating investment opportunities in biosimilars production – for the operators in radiation-induced myelosuppression treatment landscape. As there is a considerable cost difference of around 20% between originator biologics and biosimilars, patients are inclined more towards an economical means of treatment, thereby fueling the scope of penetration of radiation-induced myelosuppression treatment in coming years.

Backed by a majority of established players housing strong bases across North America, especially the US, the report indicates a steady growth outlook for the radiation-induced myelosuppression treatment market in the region. North America will reportedly continue to account for over 65% share in the global market value.

New product launches currently mark the top developmental strategy adopted by leading companies competing in the radiation-induced myelosuppression treatment market. A majority of key players are also identified to focus on enhancing their geographical foothold in global radiation-induced myelosuppression treatment landscape. The report in a distinct section covers some of the key competitors operating in radiation-induced myelosuppression treatment marketplace, emphasizing their financial as well as strategic profiles in depth.

A few of the profiled companies include Pfizer Inc., Janssen Pharmaceutical NV, Janssen Global Services, LLC (Johnson & Johnson), Amgen Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Novartis AG, and Partner Therapeutics, Inc.

In the highly consolidated competitive landscape of global radiation-induced myelosuppression treatment, the three top ranking companies, i.e. Janssen Pharmaceutical NV, Amgen Inc., and Teva Pharmaceutical Industries Ltd. dominate in terms of market value. These players continue to hold winning revenue shares in the radiation-induced myelosuppression treatment owing to strong global presence and a considerable number of new drug approvals. Established companies are entering strategic partnerships and collaborations with regional leaders, in an effort to achieve better penetration into regional markets.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-8116

Scope of Report

Attribute	Details
Forecast Period	2022-2028
Historical Data Available for	2013-2021
Market Analysis	Units for Volume and US$ Mn for Value
Key Regions Covered	North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA
Key Countries Covered	United States, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Russia, Poland, China, India, Thailand, Indonesia, Australia and New Zealand, Japan, GCC countries, North Africa, South Africa, others.
Key Market Segments Covered	Indication, Drug Class, Route of Administration, Distribution Channel, and Region
Key Companies Profiled	Amgen Inc. Novartis AG Teva Pharmaceutical Industries Ltd Mylan N.V. Pfizer Inc. Janssen Global Services, LLC (Johnson & Johnson) Partner Therapeutics, Inc. Mission Pharmacal Company Myelo Therapeutics GmbH Pluristem Therapeutics Inc.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-8116

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/